VHL Antibodies

Santa Cruz Biotechnology supplies a comprehensive collection of VHL Antibodies for understanding the role of the von Hippel-Lindau (VHL) protein. VHL Antibodies are available for various techniques, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). The VHL protein is a critical component of the cellular response to hypoxia and plays a significant role in regulating the degradation of hypoxia-inducible factors (HIFs). Dysregulation of VHL is associated with several cancers, particularly clear cell renal cell carcinoma, making it an important target for cancer research. Understanding VHL function and its interactions can provide insights into tumorigenesis and potential therapeutic strategies. VHL research has revealed important mechanisms in oxygen sensing and cellular adaptation to hypoxic conditions. Studying VHL pathways has enhanced our knowledge of tumor suppressor mechanisms and their role in cancer development. The relationship between VHL and angiogenesis continues to be an active area of investigation in cancer biology. Santa Cruz Biotechnology monoclonal antibodies for VHL research support scientists worldwide in advancing our understanding of cancer biology and developing new therapeutic approaches.